Supreme Court blocks controversial Purdue Pharma opioid settlement

Supreme Court ruling & bankruptcy law

• Case turns on whether Chapter 11 allows “non‑debtor third‑party releases” that permanently shield people (the Sacklers) who are not themselves in bankruptcy.
• Majority: bankruptcy courts lack authority to wipe out others’ future claims against non‑debtors; catch‑all “any other appropriate provision” can’t mean “anything goes.”
• Dissent: code is flexible and equitable; if a global deal clearly makes creditors better off, courts should be able to approve it.
• Ruling also affects future mass‑tort bankruptcies (e.g., other product or aviation cases).

Impact on victims and settlement

• Blocked deal would have delivered ~$6B (mostly from the Sacklers) to governments and individual victims, and converted Purdue into a public‑benefit entity.
• Many victims’ groups, states, and creditors backed the deal as the best realistic option: faster, more certain payouts, less litigation trauma.
• Others saw it as a “Faustian bargain”: too little money versus harm done, and morally intolerable to sell immunity to billionaires.
• After ruling, compensation is delayed and uncertain; some expect less money overall, others think new litigation could yield more but over many years.

Sacklers’ conduct and liability

• Discussion emphasizes internal evidence that Purdue:
  • Knew about addiction risks and designed dosing that fostered dependence.
  • Aggressively marketed OxyContin as safer/less addictive, especially for chronic pain.
  • Greatly increased payouts to the family once liability loomed (“milking” before bankruptcy).
• Debate over tools to reach family wealth: fraudulent transfer, piercing the corporate veil, criminal charges, asset seizure, garnishment.
• Many argue fines are insufficient; call for prison and full or near‑total asset stripping.

Doctors, FDA, and regulators

• Split views on physician responsibility:
  • Some stress doctors knew opioids were addictive, benefited from pharma incentives, and ran “pill mills.”
  • Others note misleading marketing, weak evidence‑appraisal training, time pressure, and system‑wide “treat pain aggressively” policies.
• Questions about FDA’s role, regulatory capture, and self‑submitted industry studies.

Court politics and institutional trust

• Unusual ideological lineup (conservatives plus Jackson in majority; Roberts/Kagan/Sotomayor/Kavanaugh dissenting) used both to:
  • Argue the Court is more complex than a simple partisan body.
  • And to argue recent patterns still show strong ideological blocs on many issues.
• Broader debate over “textualism vs pragmatism” and whether this ruling prioritizes retribution/deterrence over restitution.

Opioids, addiction, and drug policy

• Extensive side discussion on:
  • Scale of opioid deaths and broader social damage.
  • Comparisons to tobacco and other drugs.
  • Stigma, chronic pain treatment, and how supply‑side crackdowns can push users to more dangerous street opioids (fentanyl).
• Some argue systemic causes (inequality, consumer culture, inadequate pain and addiction care) go beyond Purdue, even if Purdue amplified the crisis.